期刊文献+

ELISA检测肿瘤患者热休克蛋白90α的影响因素分析 被引量:5

Analysis of affecting factors in the detection of tumor patients heat shock protein 90α using ELISA
原文传递
导出
摘要 目的探讨影响ELISA定量检测肿瘤患者血浆中热休克蛋白90d(Hsp90a)的不同相关因素。方法实验采用比对研究,分别使用含EDTA—K2和EDTA.K3抗凝剂的真空采血管采集2012年3至7月在中国医学科学院肿瘤医院门诊就诊的72例肿瘤患者全血标本,进行Hsp90α定量检测。配制含不同浓度内源性干扰物质(溶血血红蛋白、乳糜等)的血浆样本,与正常样本同时检测Hsp90α的浓度。使用t检验分析各配对血浆样本中Hsp90α浓度值的差异。结果EDTA—K2抗凝管采集的血标本中Hsp9001浓度为(156.4±67.6)ng/ml,EDTA—K3抗凝管采集的血标本中浓度为(53.9±26.6)ng/ml,差异有统计学意义(t=10.68,P〈0.01)。乳糜浓度〉5%时血标本中Hsp90d浓度低于(34.3±2.0)ng/ml,正常血标本中浓度为(37.7±1.3)ng/ml,差异有统计学意义(t=3.96,P〈0.05)。不同浓度溶血的血标本中Hsp90仪浓度均大于(94.2±7.2)ng/ml,正常血标本中浓度为(67.0±4.4)ng/ml,差异有统计学意义(t=-9.17,P〈0.05)。类风湿因子(RF)浓度为25U/ml的血标本中浓度为(39.0±3.5)ng/ml,正常血标本中浓度为(35.3±1.7)ng/ml,差异有统计学意义(t=-2.37,P〈0.05)。黄疸浓度为4g/L时的血标本中浓度为(38.4±2.1)ng/ml,正常血标本中浓度为(35.7±1.4)ng/ml,差异有统计学意义(t=-2.97,P〈0.05)。结论外源性物质和内源性物质对ELISA检测血浆中Hsp90α的浓度均有干扰,在实验过程中应严格做好质量控制,尽量避免假阳性及假阴性结果的出现。 [ Abstract ] Objective To investigate the interference of the related factors on detection of heat shock protein 90α (Hsp90α) by ELISA. Methods Seventy-two blood samples were collected in Cancer Institute/ Hospital, Chinese Academy of Medical Sciences from March to July 2012, which collected simultaneously via various anticoagulants of EDTA-K2 and EDTA-K3. Different samples which were matched with normal plasma specimens, containing endogenous interfering substances (hemolytic hemoglobin, chyle) were prepared and analyzed. The differences of Hsp90α concentration in paired group were analyzed by t-test. Results There were statistical differences between EDTA-K2 group [ ( 156.4 ± 67.6) ng/ml ] and EDTA-K3 group [ (53.9 ± 26. 6) ng/ml, t = 10. 68, P 〈 0. 01 ]. Comparing the levels of Hsp90αin the chyle concentration lower than 5% groups[ (34. 3 ± 2. 0) ng/ml] with normal control group[ (37. 7 ± 1.3 ) ng/ml ], the value had significant difference ( t = 3.96, P 〈 0. 05 ). The levels of Hsp90ct in hemolytic hemoglobin [ (94. 2 ± 7. 2) ng/ml were significantly higher than this of normal control [ (67.0 ± 4. 4) ng/ml, t = - 9. 17, P 〈 0. 05 ]. The levels of Hsp90ct in RF concentration 25 U/ml group [ ( 39.0 ± 3.5 ) ng/ml ] were higher than this of normal control[ ( 35.3 ± 1.7 ) ng/ml, t = - 2. 37, P 〈 0. 05 ]. The levels of Hsp90αin bilirubin concentration 4 g/L group [ ( 38.4 ± 2. 1 ) ng/ml ] were higher than this of normal control [ ( 35.7 ± 1.4) ng/ml, t = - 2. 97, P 〈 0. 05 ]. Conclusions Exogenous and endogenous substances would interfere the detection of Hsp90ct in tumor patients using ELISA method. Quality control should be implemented strictly during the experiments in order to avoid false positive and false negative results.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2013年第12期1100-1103,共4页 Chinese Journal of Laboratory Medicine
基金 基金项目:国家高技术研究发展计划(863计划)资助项目(2011AA02A110) 国家重大新药创制科技重大专项资助项目(2008ZX09312) 国家重大新药创制科技重大专项资助项目(2012ZX09303012)
关键词 肿瘤 HSP90热休克蛋白质类 酶联免疫吸附测定 Neoplasms HSP90 heat-shock proteins Enzyme-linked immunosorbent assay
  • 相关文献

参考文献4

二级参考文献15

  • 1Sapin R,Agin A,Gasser F.Misleading high thyrotropin results obtained with a two-site immunometric assay involving a chimeric antibody.Clin Chem,2004,50(5):946-948.
  • 2Fabris F, Ahmad S, Cella G, et al. Pathophysiology of heparin - induced thrombocytopenia. Clinical and diagnostic implications- a review. Arch Pathol Lab Med, 2000,124(11):1657.
  • 3Hillyer CD. EDTA- dependent leukoagglutination. Am J Clin Pathol,1990, 94(15) :458.
  • 4Narayanall S. The preanalytic phase. An important componet o laboratory medicine. Am J Clin Pathol,2000,113(12) :439.
  • 5Laube N, Jansen B, Hesse A. Citric acod or citrtes in urine: which should we focus on in the prevention of calcium oxalate crystals and stones? Urol Res, 2002,30(5):336.
  • 6Narita M, Hino M, Takubo T, et al. Analogues of ethylenediaminetetraacetic acid and sodium fluoriide as anticoagulants. Osaka City Med J, 2000,46(1):71.
  • 7Stahl M, Jorgensen LG, Hyltoft Petersen P, etal. Optimization of preanalytical conditions and analysis of plasma glucose. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest, 2001,61(3):169.
  • 8谭爱华.ELISA法检测中应注意的问题[J].实用医技杂志,2008,15(19):2496-2497. 被引量:18
  • 9段金霞,冯涛聚,苏文凡.酶联免疫吸附试验法检测HBV血清标志物的分析前质量控制[J].职业与健康,2008,24(24):2674-2675. 被引量:2
  • 10丛玉隆.止血与血栓实验的质量控制应注意的几个问题[J].临床检验信息导报,1998,5(2):41-48. 被引量:11

共引文献133

同被引文献52

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部